Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin informs us about mpox circulation, the Marburg virus outbreak in Rwanda, new recommendations for the RSV and pneumococcal vaccines by the CDC, the beginning of influenza season, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, contrasting public health concerns between the US and the UK, what the risk of SARS-CoV-2 transmission is when indoors, the difference between NVX-CoV2327 and BNT162b2 for adolescents, why 65 years and older should get a second boost of the COVID-19 vaccine, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, the clinical trial for evaluating how novel treatments of COVID-19 affect long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome after SARS-CoV-2 infection.

Subscribe (free): Apple Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Grim marker: mpox over a 1000 deaths in Africa (CIDRAP)
• Global trend of mpox outbreak 2022-2024 (WHO)
• Second time mpox is a global public health emergency (Reuters)
• Mpox variant in Germany (Reuters)
• Epidemiological analysis of confirmed mpox cases in Burundi (EuroSurveillance)
• The 63rd case of Marburg virus infections in Rwanda (CIDRAP)
• How to stop Marburg virus (Rwanda Biomedical Centre)
• Marburg virus fact sheet (Rwanda Biomedical Centre)
• FDA approves RSV vaccine ABRYSVO for 18-59 individuals of increased risk (Pfizer)
• Respiratory syncytial virus infection-NET (CDC)
• New  pneumococcal vaccine recommendations…..it’s a virus? (CDC Newsroom)
• Recommending PREVNAR 20, 20 valent pneumococcal conjugate vaccine for 50 and over (Pfizer)
• And one more, CAPVEXIVE, pneumococcal 21 valent conjugate vaccine (Merck)
• Penumococcoal